Breast Health

The lack of data on the possible connection between race and breast cancer prognosis is what led a group of Mount Sinai researchers to conduct this new multicenter, cross-sectional study.

A study from the Long Island Breast Cancer Study Project (LIBCSP) investigated the association between menopausal hormone therapy (MHT) and mortality outcomes among breast cancer survivors.

New research shows that, when seeking treatment for cancer-related fatigue, breast cancer survivors underutilize recommendations.

The study in the Journal of Clinical Oncology is a follow-up to a study conducted by the same authors to evaluate if pregnancy is safe in breast cancer patients who have hormone-sensitive breast cancer.

According to a new study in the American Journal of Health-System Pharmacy, chemotherapy stewardship programs may result in cost savings to both patient and health systems.

Women with ductal carcinoma in situ (DCIS) may experience higher risk of developing invasive breast cancer (IBC) and of death from breast cancer than the general population, according to new research.

New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.

The review concluded that the highest increase in MD is among current users of HRT, particularly those taking continuous estrogen plus progestin (CEP).

Currently, 38 states and the District of Columbia have enacted dense breast notification (DBN) laws mandating that mammogram results include language informing women of risks related to dense breasts.

Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.

In recent years, the United States has seen a shift in greater awareness of the importance of SDOH and toward a more comprehensive approach to healthcare.

New research indicates that women may be able to reduce menopausal symptoms by increasing their intake of fruits and vegetables (FV).

Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.

Australian researchers believe that PD-L1 may have potential as an indicator of potential response to chemotherapy in women with metastatic breast cancer. That was based on results of a randomized trial, presented at the European Society for Medical Oncology in Lugano, Switzerland.

The results show that participating in screening mammography is essential for reducing the number of deaths from breast cancer and can ultimately save lives through early detection.

Long-term adherence improvements, it appears, require personalized and sustained behavioral interventions. TMs for AI should also be personalized for individual success.

A diagnosis of vulvovaginal atrophy (VVA) in breast cancer survivors is associated with a significant increase in the burden of illness and social costs, according to an Italian Delphi Panel in the journal Supportive Care in Cancer. These findings are primarily due to a rise in comorbidities and resource utilization, but adequate treatment might reduce the impact of the condition.

Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.

Results of a new study point to a link between exposure to tamoxifen and aromatase inhibitors and reduced diagnoses of neurodegenerative diseases.

New findings shows that screening mammography that led to detection of triple-negative breast cancer (TNBC) resulted in similar outcomes for both white and African-American women.

New research from the Journal of General Internal Medicine shows that these laws are not associated with an increased understanding of the clinical implications of breast density.

The agency issued the guidance in response to concerns that some women are not receiving and/or understanding information about the risks and benefits of the devices.

While current guidelines recommend genetic testing in women with breast cancer who have relevant family history or clinical criteria, a new study examined whether it makes more sense to test all women with breast cancer.

Gadolinium-based intravenous contrast agents (GBCA) provide additional information based on signal intensity changes after GBCA administration. 

The US Preventive Services Task Force (UPSTF) recently released an updated recommendation on medications for risk reduction of primary breast cancer and which patients would benefit most from a prescription.

The US Preventive Services Task Force (USPSTF) recently released updated recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.

Almost 25% of women with breast cancer have a family history of the disease and, those who do have a higher risk of developing cancer.

BRCA mutation carrying mothers may have different risks depending on whether the mutation is BRCA1 or BRCA2.

Exposure to high levels of DDT is known to increase risk of breast cancer and new research examined whether age of exposure and of diagnosis are connected.

A recent study aimed to quantify the effectiveness of improvements in screening and treatment.